ReviewCancers2023
Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Autologous and Implant-Based Breast Reconstruction Demonstrate Equivalent Psychiatric Outcomes at Long-Term Follow-Up: Results from a Multi-Intuitional Propensity Score-Matched Analysis.Aesthetic plastic surgery · 2026Article
- Pembrolizumab induced life threatening adrenal crisis in a patient with recurrent adrenocortical carcinoma after unilateral adrenalectomy.Discover oncology · 2026Article
- Clinical Analysis of Relapse Risk in Immune-Checkpoint-Inhibitor-Related Pneumonitis.Journal of clinical medicine · 2026Article
- Effect of Immune Checkpoint Inhibitor Therapy on Biventricular and Biatrial Mechanics in Patients with Advanced Cancer: A Short-Term Follow-Up Study.Journal of clinical medicine · 2026Article
- Associations between systemic immune-inflammation index and immune-related hypothyroidism in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective study.Frontiers in oncology · 2026Article
- Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors.The Journal of clinical endocrinology and metabolism · 2025Article
- CD99 is a potential diagnostic and immunological biomarker in pan-cancer.Discover oncology · 2025Article
- Levels of serum lipids predict responses to PD-L1 inhibitors as first-line treatment in small cell lung cancer: an observational study.International journal of clinical pharmacy · 2024Observational
- Cardiac Troponin Serum Concentration Measurement Is Useful Not Only in the Diagnosis of Acute Cardiovascular Events.Journal of personalized medicine · 2024Review
- A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab.Case reports in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant neoplasms are currently one of the leading causes of morbidity and mortality worldwide, posing a major public health challenge. However, recent advances in research in cancer biology and immunity have led to the development of immunotherapy, which is now used on an everyday basis in cancer treatment in addition to surgical treatment, classical cytostatics, and radiotherapy. The efficacy of immunotherapy has promoted the great popularity of this treatment among patients, as well as significant research interest. The increasing number of patients being treated with immunotherapy not only reassures physicians of the efficacy of this technique but also shows the wide spectrum of side effects of this therapy, which has not been considered before. Immune-related adverse events may affect many systems and organs, such as digestive, cardiovascular, respiratory, skin, or endocrine organs. Most complications have a mild or moderate course, but there are life-threatening manifestations that are essential to be aware of because if they are not properly diagnosed and treated on time, they can have fatal consequences. The purpose of this paper was to present the results of a literature review on the current state of knowledge on life-threatening endocrine side effects (such as adrenal crisis, thyroid storm, myxoedema crisis, diabetic ketoacidosis, and severe hypocalcaemia) of immune checkpoint inhibitors to provide information on symptoms, diagnostics, and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.